dihydrexidine
Small moleculeexperimental
Dihydrexidine (DAR-0100) is a moderately selective full agonist at the dopamine D1 and D5 receptors. It has approximately 10-fold selectivity for D1 and D5 over the D2 receptor. Although dihydrexidine has some affinity for the D2 receptor, it has functionally selective (highly biased) D2 signaling, thereby explaining why it lacks D2 agonist behavioral qualities. — Wikipedia
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 20, 1999 (NCT00000348)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Dopamine D5 receptorAGONIST
DRD5 agonist
- Dopamine D1 receptorAGONIST
DRD1 agonist
Chemistry & pharmacology
Loading structure…
SMILES
Oc1cc2c(cc1O)[C@H]1c3ccccc3CN[C@@H]1CC2- Mol. weight
- 267.33 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDihydrexidine ↗
- ChEMBLCHEMBL25856 ↗
Also known as
- 10,11-dihydroxyhexahydrobenzo(a)phenanthridine
- benzo(a)phenanthridine-10,11-diol, 5,6,6a,7,8,12b-hexahydro-, trans-
- dar0100a
- dar 0100a
- dar-0100a
- dihydrexidine
- dihydrexidine
- dihydrexidine
- dihydrexidine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00000348 | Phase 1 | Sep 20, 1999 | Friends Research Institute, Inc., National Institute on Drug Abuse (NIDA) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Friends Research Institute, Inc. | Academic/Hospital | 1 | 0 | 1 | 1999 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 1 | 1 | 1999 |
2 organizations
Page 1 / 1